Radioiodinated antibody targeting of the HER-2/neu oncoprotein

被引：19
|
作者：
Xu, FJ
Yu, YH
Bae, DS
Zhao, XG
Slade, SK
Boyer, CM
Bast, RC
Zalutsky, MR
机构：
[1] UNIV TEXAS,MD ANDERSON CANCER CTR,DIV MED,HOUSTON,TX 77030
[2] DUKE UNIV,MED CTR,DEPT RADIOL,DURHAM,NC 27710
[3] DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710
来源：
NUCLEAR MEDICINE AND BIOLOGY | 1997年 / 24卷 / 05期
关键词：
c-erbB-2 (HER-2/neu); ovarian cancer; monoclonal antibody; radioiodination; tumor;
D O I：
10.1016/S0969-8051(97)00065-6
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
The HER-2/neu oncogene encodes a 185 kDa phosphoglycoprotein that is overexpressed in breast, ovarian and other cancers. Seven monoclonal antibodies reactive with this oncoprotein were labeled with I-131. In vitro experiments with SKOv3 9002-18 cells determined binding affinity, internalization and degradation. The biodistribution of these antibodies in comparison to I-125-labeled nonspecific antibody was measured in athymic mice with SKOv3 9002-18 ovarian carcinoma xenografts. Antibody 520C9 exhibited the highest and most specific retention in tumor, peaking at 17.4 +/- 5.6% ID/g at 24 h. (C) 1997 Elsevier Science Inc.
引用
收藏
页码：451 / 459
页数：9
相关论文
共 50 条
  • [31] Utility of Serum HER-2/ neu in Prediction of Tissue HER-2 /neu Status of Primary Breast Cancer
    Mokhtari, Maral
    Khosravi, Mohammad Hadi
    MIDDLE EAST JOURNAL OF CANCER, 2021, 12 (04) : 483 - 490
  • [32] HER-2 therapy. HER-2/neu diagnostics in breast cancer
    Walter P Carney
    Kim Leitzel
    Suhail Ali
    Rainer Neumann
    Allan Lipton
    Breast Cancer Research, 9
  • [33] Complex formation between the shed antigen of HER-2/neu and the monoclonal anti-HER-2/neu antibody trastuzumab.
    Lueftner, DI
    Schaller, G
    Henschke, P
    Amin, R
    Geppert, R
    Wernecke, K
    Possinger, K
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S49 - S49
  • [34] Soluble HER-2/neu neutralizes biologic effects of anti-HER-2/neu antibody on breast cancer cells in vitro
    Brodowicz, T
    Wiltschke, C
    Budinsky, AC
    Krainer, M
    Steger, GG
    Zielinski, CC
    INTERNATIONAL JOURNAL OF CANCER, 1997, 73 (06) : 875 - 879
  • [35] Serum HER-2/neu levels in clinical studies with lapatinib in HER-2/neu positive breast cancer
    Maltzman, J.
    Blackwell, K.
    Stein, S.
    Martin, A.
    Westland, R.
    Burstein, H.
    Gomez, H.
    Gartner, N.
    Platek, G.
    Newmiller, M.
    Lipton, A.
    Carney, W. P.
    CLINICAL CHEMISTRY, 2008, 54 (06) : A130 - A130
  • [36] Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth
    Mann, M
    Sheng, HM
    Shao, JY
    Williams, CS
    Pisacane, PI
    Sliwkowski, MX
    DuBois, RN
    GASTROENTEROLOGY, 2001, 120 (07) : 1713 - 1719
  • [37] Antibody immunity to the HER-2/neu oncogenic protein in patients with colorectal cancer
    Ward, RL
    Hawkins, NJ
    Coomber, D
    Disis, ML
    HUMAN IMMUNOLOGY, 1999, 60 (06) : 510 - 515
  • [38] HER-2/neu (c-erbB-2) oncoprotein in hyperplastic endometrial polyps detected in two cats
    Misirlioglu, Deniz
    Nak, Deniz
    Ozyigit, Musa Ozgur
    Nak, Yavuz
    Akkoc, Ahmet
    JOURNAL OF FELINE MEDICINE AND SURGERY, 2009, 11 (10) : 885 - 888
  • [39] The emerging role of monitoring serum HER-2/neu oncoprotein levels in women with metastatic breast cancer
    Carney, WP
    LABORATORY MEDICINE, 2003, 34 (01) : 58 - 64
  • [40] Salivary duct carcinoma -: A highly aggressive salivary gland tumor with HER-2/neu oncoprotein overexpression
    Skálová, A
    Stárek, I
    Kucerová, V
    Szépe, P
    Plank, L
    PATHOLOGY RESEARCH AND PRACTICE, 2001, 197 (09) : 621 - 626
12345